IXICO PLC (LSE:IXI) — Market Cap & Net Worth
Market Cap & Net Worth: IXICO PLC (IXI)
IXICO PLC (LSE:IXI) has a market capitalization of $199.82K (GBX1.64 Billion) as of September 19, 2026. Listed on the LSE stock exchange, this UK-based company holds position #31336 globally and #1031 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying IXICO PLC's stock price GBX7.50 by its total outstanding shares 218974282 (218.97 Million). Also see IXI total asset value for a full breakdown of the balance sheet.
IXICO PLC Market Cap History: 2015 to 2026
IXICO PLC's market capitalization history from 2015 to 2026. Data shows change from $825.93K to $199.82K (-12.80% CAGR). Also see IXI cash flow metrics for how efficiently the company converts equity into cash flow.
Index Memberships
IXICO PLC is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$912.31 Million | 0.02% | #296 of 722 |
Weight: IXICO PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
IXICO PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how IXICO PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check IXICO PLC share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.05x
IXICO PLC's market cap is 0.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $839.25K | $3.27 Million | -$2.12 Million | 0.26x | N/A |
| 2017 | $972.46K | $4.10 Million | -$1.54 Million | 0.24x | N/A |
| 2018 | $626.11K | $5.39 Million | -$668.00K | 0.12x | N/A |
| 2019 | $2.41 Million | $7.56 Million | $432.00K | 0.32x | 5.58x |
| 2020 | $2.73 Million | $9.53 Million | $952.00K | 0.29x | 2.87x |
| 2021 | $1.56 Million | $9.19 Million | $1.51 Million | 0.17x | 1.03x |
| 2022 | $679.39K | $8.64 Million | $1.03 Million | 0.08x | 0.66x |
| 2023 | $333.04K | $6.67 Million | -$1.18 Million | 0.05x | N/A |
| 2024 | $313.05K | $5.77 Million | -$2.00 Million | 0.05x | N/A |
| 2025 | $313.05K | $6.53 Million | -$1.65 Million | 0.05x | N/A |
Competitor Companies of IXI by Market Capitalization
Companies near IXICO PLC in the global market cap rankings as of September 19, 2026. Review IXICO PLC tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to IXICO PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
IXICO PLC Historical Marketcap From 2015 to 2026
Between 2015 and today, IXICO PLC's market cap moved from $825.93K to $ 199.82K, with a yearly change of -12.80%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX199.82K | -36.17% |
| 2025 | GBX313.05K | 0.00% |
| 2024 | GBX313.05K | -6.00% |
| 2023 | GBX333.04K | -50.98% |
| 2022 | GBX679.39K | -56.41% |
| 2021 | GBX1.56 Million | -42.93% |
| 2020 | GBX2.73 Million | +13.26% |
| 2019 | GBX2.41 Million | +285.11% |
| 2018 | GBX626.11K | -35.62% |
| 2017 | GBX972.46K | +15.87% |
| 2016 | GBX839.25K | +1.61% |
| 2015 | GBX825.93K | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of IXICO PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $199.82K USD |
| MoneyControl | $199.82K USD |
| MarketWatch | $199.82K USD |
| marketcap.company | $199.82K USD |
| Reuters | $199.82K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About IXICO PLC
IXICO plc provides data analytics services to biopharmaceutical industry in the United States, the United Kingdom, the Netherlands, Denmark, Switzerland, Ireland, Europe, and internationally. The company offers collection, analysis, management, and reporting on gathered clinical study data; neurological diseases data collection and analysis; and sales and marketing services. It also provides imag… Read more